The application of next-generation sequencing elucidated the molecular landscape of MDS by unraveling the sequential acquisition of recurrent somatic mutations in driver and subclonal genes such as DNMT3A, TET2, IDH1/2, ASXL1, TP53, RUNX1, SF3B1, U2AF1, SRSF2, and ZRSR2 [1,2,3,4,5,6,7]. The gene discussed is TP53; the disease is myelodysplastic syndrome.